Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UGN-103 rollover durability study after BL013
2026-526359-75-00Phase 4Authorised
- Sponsor
- UroGen Pharma
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, open-label, single-arm trial of UGN-103 in non-muscle-invasive bladder cancer (NMIBC), sponsored by UroGen Pharma. Primary endpoint: Duration of response. Planned start Oct 2026; status: authorised.
02
Drugs
UGN-103
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2026-526359-75-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526359-75-00.